Login to Your Account

Iomx raises $45M for tumor-derived immune checkpoint targets

By Cormac Sheridan
Staff Writer

Thursday, September 22, 2016

DUBLIN – A mere four months after its formation, German startup Iomx Therapeutics GmbH raised €40 million (US$44.6 million) in a series A round to develop antibody-based therapeutics against tumor-derived immune checkpoint targets.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription